Table of Contents Author Guidelines Submit a Manuscript
Journal of Biomedicine and Biotechnology
Volume 2011 (2011), Article ID 379123, 7 pages
http://dx.doi.org/10.1155/2011/379123
Review Article

Clinical Cancer Therapy by NK Cells via Antibody-Dependent Cell-Mediated Cytotoxicity

1Department of Human Oncology, University of Wisconsin, Madison, WI 53705, USA
2Department of Pediatrics, University of Wisconsin, Madison, WI 53705, USA
3Paul P. Carbone Comprehensive Cancer Center, University of Wisconsin, Madison, WI 53792-6164, USA

Received 1 February 2011; Accepted 16 March 2011

Academic Editor: Roberto Biassoni

Copyright © 2011 Kory L. Alderson and Paul M. Sondel. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. S. Orange, “Human natural killer cell deficiencies and susceptibility to infection,” Microbes and Infection, vol. 4, no. 15, pp. 1545–1558, 2002. View at Publisher · View at Google Scholar
  2. J. A. Trapani and I. Voskoboinik, “Infective, neoplastic, and homeostatic sequelae of the loss of perforin function in humans,” Advances in experimental medicine and biology, vol. 601, pp. 235–242, 2007. View at Google Scholar · View at Scopus
  3. J. V. Ravetch and S. Bolland, “IgG Fc receptors,” Annual Review of Immunology, vol. 19, pp. 275–290, 2001. View at Publisher · View at Google Scholar · View at Scopus
  4. P. M. Sondel and J. A. Hank, “Antibody-directed, effector cell-mediated tumor destruction,” Hematology/Oncology Clinics of North America, vol. 15, no. 4, pp. 703–721, 2001. View at Publisher · View at Google Scholar · View at Scopus
  5. F. Navid, V. M. Santana, and R. C. Barfield, “Anti-GD2 antibody therapy for GD2-expressing tumors,” Current Cancer Drug Targets, vol. 10, no. 2, pp. 200–209, 2010. View at Publisher · View at Google Scholar · View at Scopus
  6. K. P. Garnock-Jones, G. M. Keating, and L. J. Scott, “Trastuzumab: a review of its use as adjuvant treatment in human epidermal growth factor receptor 2 (HER2)-positive early breast cancer,” Drugs, vol. 70, no. 2, pp. 215–239, 2010. View at Publisher · View at Google Scholar · View at Scopus
  7. J. García-Foncillas and E. Díaz-Rubio, “Progress in metastatic colorectal cancer: growing role of cetuximab to optimize clinical outcome,” Clinical and Translational Oncology, vol. 12, no. 8, pp. 533–542, 2010. View at Publisher · View at Google Scholar
  8. M. C. Winter and B. W. Hancock, “Ten years of rituximab in NHL,” Expert Opinion on Drug Safety, vol. 8, no. 2, pp. 223–235, 2009. View at Publisher · View at Google Scholar · View at Scopus
  9. M. R. Albertini, J. A. Hank, and P. M. Sondel, “Native and genetically engineered anti-disialoganglioside monoclonal antibody treatment of melanoma,” Cancer Chemotherapy and Biological Response Modifiers, vol. 22, pp. 789–797, 2005. View at Google Scholar · View at Scopus
  10. R. K. Yang and P. M. Sondel, “Anti-GD2 strategy in the treatment of neuroblastoma,” Drugs Future, vol. 35, no. 8, p. 665, 2010. View at Google Scholar
  11. F. Nimmerjahn and J. V. Ravetch, “Fcγ receptors as regulators of immune responses,” Nature Reviews Immunology, vol. 8, no. 1, pp. 34–47, 2008. View at Publisher · View at Google Scholar · View at Scopus
  12. D. C. Delgado, J. A. Hank, J. Kolesar et al., “Genotypes of NK cell KIR receptors, their ligands, and Fcγ receptors in the response of neuroblastoma patients to Hu14.18-IL2 immunotherapy,” Cancer Research, vol. 70, no. 23, pp. 9554–9561, 2010. View at Publisher · View at Google Scholar
  13. A. Beano, E. Signorino, A. Evangelista et al., “Correlation between NK function and response to trastuzumab in metastatic breast cancer patients,” Journal of Translational Medicine, vol. 6, article no. 25, 2008. View at Publisher · View at Google Scholar · View at Scopus
  14. J. A. Hank, G. Weil-Hillman, J. E. Surfus, J. A. Sosman, and P. M. Sondel, “Addition of interleukin-2 in vitro augments detection of lymphokine-activated killer activity generated in vivo,” Cancer Immunology Immunotherapy, vol. 31, no. 1, pp. 53–59, 1990. View at Publisher · View at Google Scholar · View at Scopus
  15. J. R. Ortaldo, C. Woodhouse, and A. C. Morgan, “Analysis of effector cells in human antibody-dependent cellular cytotoxicity with murine monoclonal antibodies,” Journal of Immunology, vol. 138, no. 10, pp. 3566–3572, 1987. View at Google Scholar · View at Scopus
  16. H. H. Van Ojik, L. Bevaart, C. E. Dahle et al., “CpG-A and B oligodeoxynucleotides enhance the efficacy of antibody therapy by activating different effector cell populations,” Cancer Research, vol. 63, no. 17, pp. 5595–5600, 2003. View at Google Scholar · View at Scopus
  17. D. J. Betting, R. E. Yamada, K. Kafi, J. Said, N. Van Rooijen, and J. M. Timmerman, “Intratumoral but not systemic delivery of CpG oligodeoxynucleotide augments the efficacy of anti-CD20 monoclonal antibody therapy against B Cell lymphoma,” Journal of Immunotherapy, vol. 32, no. 6, pp. 622–631, 2009. View at Publisher · View at Google Scholar · View at Scopus
  18. H. E. Kohrt, R. Houot, M. J. Goldstein et al., “CD137 stimulation enhances the antilymphoma activity of anti-CD20 antibodies,” Blood, vol. 117, no. 8, pp. 2423–2432, 2011. View at Publisher · View at Google Scholar
  19. J. A. Bowles, S. Y. Wang, B. K. Link et al., “Anti-CD20 monoclonal antibody with enhanced affinity for CD16 activates NK cells at lower concentrations and more effectively than rituximab,” Blood, vol. 108, no. 8, pp. 2648–2654, 2006. View at Publisher · View at Google Scholar · View at Scopus
  20. L. M. Weiner, R. Surana, and S. Wang, “Monoclonal antibodies: versatile platforms for cancer immunotherapy,” Nature Reviews Immunology, vol. 10, no. 5, pp. 317–327, 2010. View at Publisher · View at Google Scholar · View at Scopus
  21. W. Lin, C. J. Voskens, X. Zhang et al., “Fc-dependent expression of CD137 on human NK cells: insights into “agonistic” effects of anti-CD137 monoclonal antibodies,” Blood, vol. 112, no. 3, pp. 699–707, 2008. View at Publisher · View at Google Scholar · View at Scopus
  22. R. Parihar, J. Dierksheide, Y. Hu, and W. E. Carson, “IL-12 enhances the natural killer cell cytokine response to Ab-coated tumor cells,” Journal of Clinical Investigation, vol. 110, no. 7, pp. 983–992, 2002. View at Publisher · View at Google Scholar · View at Scopus
  23. R. Parihar, P. Nadella, A. Lewis et al., “A phase I study of interleukin 12 with trastuzumab in patients with human epidermal growth factor receptor-2-overexpressing malignancies: analysis of sustained interferon γ production in a subset of patients,” Clinical Cancer Research, vol. 10, no. 15, pp. 5027–5037, 2004. View at Publisher · View at Google Scholar
  24. K. R. Schultz, J. P. Klarnet, D. J. Peace et al., “Monoclonal antibody therapy of murine lymphoma: enhanced efficacy by concurrent administration of interleukin 2 or lymphokine-activated killer cells,” Cancer Research, vol. 50, no. 17, pp. 5421–5425, 1990. View at Google Scholar · View at Scopus
  25. M. Watanabe, T. Kubota, M. Kitajima, and S. Hakomori, “Synergetic effect of interleukin-2 and cellular cytotoxicity against a novel tumor-associated carbohydrate antigen Le(a)/Le(a) (dimeric Le(a) mediated by monoclonal antibody NCC-ST-421 in adoptive immunization using SCID mice,” Cancer Immunology Immunotherapy, vol. 37, no. 4, pp. 245–250, 1993. View at Publisher · View at Google Scholar · View at Scopus
  26. S. C. Helfand, S. A. Soergel, R. L. Donner et al., “Potential to involve multiple effector cells with human recombinant interleukin-2 and antiganglioside monoclonal antibodies in a canine malignant melanoma immunotherapy model,” Journal of Immunotherapy, vol. 16, no. 3, pp. 188–197, 1994. View at Google Scholar
  27. Z. C. Neal, J. C. Yang, A. L. Rakhmilevich et al., “Enhanced activity of hu14.18-IL2 immunocytokine against murine NXS2 neuroblastoma when combined with interleukin 2 therapy,” Clinical Cancer Research, vol. 10, no. 14, pp. 4839–4847, 2004. View at Publisher · View at Google Scholar · View at Scopus
  28. S. Iida, R. Kuni-Kamochi, K. Mori et al., “Two mechanisms of the enhanced antibody-dependent cellular cytotoxicity (ADCC) efficacy of non-fucosylated therapeutic antibodies in human blood,” BMC Cancer, vol. 9, article no. 58, 2009. View at Publisher · View at Google Scholar · View at Scopus
  29. T. Shinkawa, K. Nakamura, N. Yamane et al., “The absence of fucose but not the presence of galactose or bisecting N-acetylglucosamine of human IgG1 complex-type oligosaccharides shows the critical role of enhancing antibody-dependent cellular cytotoxicity,” Journal of Biological Chemistry, vol. 278, no. 5, pp. 3466–3473, 2003. View at Publisher · View at Google Scholar · View at Scopus
  30. L. S. Sorkin, M. Otto, W. M. Baldwin et al., “Anti-GD with an FC point mutation reduces complement fixation and decreases antibody-induced allodynia,” Pain, vol. 149, no. 1, pp. 135–142, 2010. View at Publisher · View at Google Scholar · View at Scopus
  31. S. D. Gillies, D. Young, K. M. Lo, and S. Roberts, “Biological activity and in vivo clearance of antitumor antibody/cytokine fusion proteins,” Bioconjugate Chemistry, vol. 4, no. 3, pp. 230–235, 1993. View at Google Scholar · View at Scopus
  32. J. A. Hank, J. E. Surfus, J. Gan et al., “Activation of human effector cells by a tumor reactive recombinant anti-ganglioside GD interleukin-2 fusion protein (ch14.18-IL2),” Clinical Cancer Research, vol. 2, no. 12, pp. 1951–1959, 1996. View at Google Scholar · View at Scopus
  33. B. H. Yamane, J. A. Hank, M. R. Albertini, and P. M. Sondel, “The development of antibody-IL-2 based immunotherapy with hu14.18-IL2 (EMD-273063) in melanoma and neuroblastoma,” Expert Opinion on Investigational Drugs, vol. 18, no. 7, pp. 991–1000, 2009. View at Publisher · View at Google Scholar · View at Scopus
  34. E. E. Johnson, H. D. Lum, A. L. Rakhmilevich et al., “Intratumoral immunocytokine treatment results in enhanced antitumor effects,” Cancer Immunology, Immunotherapy, vol. 57, no. 12, pp. 1891–1902, 2008. View at Publisher · View at Google Scholar · View at Scopus
  35. H. N. Lode, R. Xiang, N. M. Varki, C. S. Dolman, S. D. Gillies, and R. A. Reisfeld, “Targeted interleukin-2 therapy for spontaneous neuroblastoma metastases to bone marrow,” Journal of the National Cancer Institute, vol. 89, no. 21, pp. 1586–1594, 1997. View at Google Scholar · View at Scopus
  36. I. N. Buhtoiarov, Z. C. Neal, J. Gan et al., “Differential internalization of hu14.18-IL2 immunocytokine by NK and tumor cell: impact on conjugation, cytotoxicity, and targeting,” Journal of Leukocyte Biology, vol. 89, no. 4, pp. 625–638, 2011. View at Google Scholar
  37. J. A. A. Gubbels, B. Gadbaw, I. N. Buhtoiarov et al., “Ab-IL2 fusion protein mediate NK cell immune synapse formation by polarizing CD25 to the target cell-effector cell interface,” Cancer Immunology and Immunotherapy. Manuscript Submitted.
  38. J. M. Maris, “Recent advances in neuroblastoma,” New England Journal of Medicine, vol. 362, no. 23, pp. 2154–2211, 2010. View at Google Scholar · View at Scopus
  39. A. L. Yu, A. L. Gilman, M. F. Ozkaynak et al., “Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma,” New England Journal of Medicine, vol. 363, no. 14, pp. 1324–1334, 2010. View at Publisher · View at Google Scholar
  40. S. Shusterman, W. B. London, S. D. Gillies et al., “Antitumor activity of Hu14.18-IL2 in patients with relapsed/refractory neuroblastoma: a Children's Oncology Group (COG) phase II study,” Journal of Clinical Oncology, vol. 28, no. 33, pp. 4969–4975, 2010. View at Publisher · View at Google Scholar
  41. S. Dall'Ozzo, S. Tartas, G. Paintaud et al., “Rituximab-dependent cytotoxicity by natural killer cells: influence of FCGR3A polymorphism on the concentration-effect relationship,” Cancer Research, vol. 64, no. 13, pp. 4664–4669, 2004. View at Publisher · View at Google Scholar · View at Scopus
  42. H. R. Koene, M. Kleijer, J. Algra, D. Roos, A. E. G. KR. Von Dem Borne, and M. De Haas, “FcγRIIIa-158V/F polymorphism influences the binding of IgG by natural killer cell FCγRIIIa, independently of the FCγRIIIa-48L/R/H phenotype,” Blood, vol. 90, no. 3, pp. 1109–1114, 1997. View at Google Scholar · View at Scopus
  43. H. M. Dijstelbloem, R. H. M. Scheepers, W. W. Oost et al., “Fcγ receptor polymorphisms in Wegener's granulomatosis: risk factors for disease relapse,” Arthritis and Rheumatism, vol. 42, no. 9, pp. 1823–1827, 1999. View at Publisher · View at Google Scholar · View at Scopus
  44. J. Wu, J. C. Edberg, P. B. Redecha et al., “A novel polymorphism of FcγRIIIa (CD16) alters receptor function and predisposes to autoimmune disease,” Journal of Clinical Investigation, vol. 100, no. 5, pp. 1059–1070, 1997. View at Google Scholar · View at Scopus
  45. M. R. Jenkins, A. Tsun, J. C. Stinchcombe, and G. M. Griffiths, “The strength of T cell receptor signal controls the polarization of cytotoxic machinery to the immunological synapse,” Immunity, vol. 31, no. 4, pp. 621–631, 2009. View at Publisher · View at Google Scholar · View at Scopus
  46. G. Cartron, L. Dacheux, G. Salles et al., “Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcγrIIIa gene,” Blood, vol. 99, no. 3, pp. 754–758, 2002. View at Publisher · View at Google Scholar · View at Scopus
  47. A. Musolino, N. Naldi, B. Bortesi et al., “Immunoglobulin g fragment c receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer,” Journal of Clinical Oncology, vol. 26, no. 11, pp. 1789–1796, 2008. View at Publisher · View at Google Scholar · View at Scopus
  48. WU. Zhang, M. Gordon, A. M. Schultheis et al., “FCGR2A and FCGR3A polymorphisms associated with clinical outcome of epidermal growth factor receptor-expressing metastatic colorectal cancer patients treated with single-agent cetuximab,” Journal of Clinical Oncology, vol. 25, no. 24, pp. 3712–3718, 2007. View at Publisher · View at Google Scholar · View at Scopus
  49. W. K. Weng and R. Levy, “Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma,” Journal of Clinical Oncology, vol. 21, no. 21, pp. 3940–3947, 2003. View at Publisher · View at Google Scholar · View at Scopus
  50. A. H. Jonsson and W. M. Yokoyama, “Natural killer cell tolerance licensing and other mechanisms,” Advances in Immunology, vol. 101, pp. 27–79, 2009. View at Publisher · View at Google Scholar · View at Scopus
  51. C. Vilches and P. Parham, “KIR: diverse, rapidly evolving receptors of innate and adaptive immunity,” Annual Review of Immunology, vol. 20, pp. 217–251, 2002. View at Publisher · View at Google Scholar · View at Scopus
  52. M. T. Orr, W. J. Murphy, and L. L. Lanier, “'Unlicensed' natural killer cells dominate the response to cytomegalovirus infection,” Nature Immunology, vol. 11, no. 4, pp. 321–327, 2010. View at Publisher · View at Google Scholar · View at Scopus
  53. J. M. Elliott, J. A. Wahle, and W. M. Yokoyama, “MHC class I-deficient natural killer cells acquire a licensed phenotype after transfer into an MHC class I-sufficient environment,” Journal of Experimental Medicine, vol. 207, no. 10, pp. 2073–2079, 2010. View at Publisher · View at Google Scholar
  54. N. T. Joncker, N. Shifrin, F. Delebecque, and D. H. Raulet, “Mature natural killer cells reset their responsiveness when exposed to an altered MHC environment,” Journal of Experimental Medicine, vol. 207, no. 10, pp. 2065–2072, 2010. View at Publisher · View at Google Scholar
  55. W. Leung, R. Handgretinger, R. Iyengar, V. Turner, M. S. Holladay, and G. A. Hale, “Inhibitory KIR-HLA receptor-ligand mismatch in autologous haematopoietic stem cell transplantation for solid tumour and lymphoma,” British Journal of Cancer, vol. 97, no. 4, pp. 539–542, 2007. View at Publisher · View at Google Scholar · View at Scopus
  56. J. M. Venstrom, J. Zheng, N. Noor et al., “KIR and HLA genotypes are associated with disease progression and survival following autologous hematopoietic stem cell transplantation for high-risk neuroblastoma,” Clinical Cancer Research, vol. 15, no. 23, pp. 7330–7334, 2009. View at Publisher · View at Google Scholar · View at Scopus
  57. N. Anfossi, P. André, S. Guia et al., “Human NK cell education by inhibitory receptors for MHC class I,” Immunity, vol. 25, no. 2, pp. 331–342, 2006. View at Publisher · View at Google Scholar · View at Scopus
  58. R. Kiessling, E. Klein, and H. Wigzell, “'Natural' killer cells in the mouse. I. Cytotoxic cells with specificity for mouse Moloney leukemia cells. Specificity and distribution according to genotype,” European Journal of Immunology, vol. 5, no. 2, pp. 112–117, 1975. View at Google Scholar · View at Scopus